While several molecular markers that are used to evaluate the development and prognosis of bladder cancer have been studied, the limited value of these established markers has created the need for ...

The growing sophistication of tumor molecular profiling has helped to slowly transition oncologic care toward a more personalized approach in different tumor types, including in bladder cancer. The ...

Armando, a 71-year-old with an active lifestyle, was midway through a round of golf when a strange sensation crept into his ...

A new report dives into the evolving clinical trial landscape and transformative therapies changing lives for bladder cancer ...

Financially, UroGen has a market cap of $464mn and a cash runway of 8-9 quarters, despite facing patent challenges from Teva.

Trial findings show long-term recurrence-free survival in patients with low-grade upper tract urothelial cancer treated with ...

Medically reviewed by Steffini Stalos, DO Bladder cancer occurs when cancerous cells form in the tissues of the bladder, the ...

Rik Bryan, Professor in Urothelial Cancer Research and Director of the Bladder Cancer Research Centre at the University of Birmingham and first author of the study said: "Bladder cancer is a ...

Some patients with low-grade Ta nonmuscle-invasive bladder cancer (LG Ta NMIBC) can experience recurrence after many years.

Gilead Sciences' TROP2-directed drug Trodelvy has missed the target in another clinical trial, this time in urothelial carcinoma, the most common form of bladder cancer. The results of the TROPiCS ...

Bladder cancer leads to significant morbidity and mortality across China. Over 92,000 people were diagnosed with bladder cancer in 2022, and approximately 41,000 deaths were reported as a result of ...